Neurocrine Biosciences (NBIX) Gross Margin (2017 - 2026)

Neurocrine Biosciences has reported Gross Margin for 10 years, with the latest figure at 98.31% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 9.0% year-over-year to 98.31%; the trailing twelve-month figure through Mar 2026 stood at 98.17% (down 35.0% YoY), and the FY2025 full-year result was 98.18%, down 38.0% from the prior year.
• Gross Margin for Q1 2026 stood at 98.31%, up from 97.82% in the prior quarter.
• The five-year high for Gross Margin was 98.71% in Q3 2024, with the low at 76.0% in Q2 2022.
• Historically, Gross Margin has averaged 96.94% across 5 years, with a median of 98.35% in 2023.
• Annual changes were most pronounced in 2022 — Gross Margin sank 2293 bps — and 2023, when it soared 2146 bps.
• Neurocrine Biosciences' Gross Margin stood at 98.13% in 2022, then advanced by 0 bps to 98.35% in 2023, then gained by 0 bps to 98.52% in 2024, then declined by 1 bps to 97.82% in 2025, then increased by 1 bps to 98.31% in 2026.
• The last three Gross Margin figures came in at 98.31% (Q1 2026), 97.82% (Q4 2025), and 98.24% (Q3 2025), per Business Quant data.